CD274 and histiocytic sarcoma: This therapeutic rationale extends to HLH, where immune dysregulation may also be mitigated by CPI, either as part of the hemophagocytic mechanism itself [18] or in patients with overlapping HLH and PD-L1-positive HS [19].